Skip to content

Study · Non-randomized trial · n = 16 · 1987

4 results

A preliminary clinical experience with reduced glutathione as protector against cisplatin-toxicity.

Oriana S, Böhm S, Spatti G, Zunino F, Di Re F

Tumori1 Aug 1987Cited by 28 (Europe PMC)

PMID3660470 (opens in a new tab)DOI10.1177/030089168707300403 (opens in a new tab)PepBankPUB-03660470
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In patients receiving chemotherapy, glutathione pretreatment reduced myelosuppression severity compared with the standard regimen without glutathione.

    In plain wordsIn patients receiving chemotherapy, glutathione reduced bone marrow suppression compared with the standard regimen without glutathione.

    Peptide
    Glutathione
    Outcome
    DecreaseMyelosuppression severity
    Study

    n = 16

    Comparator
    Standard chemotherapy without glutathione
    Outcome group
    Adverse events · Whole body
    Studied dose
    1500 mg/m2 · maximum of five consecutive coursesAs given in this study (human).

    Source sentences

    Summary
    The severity of myelosuppression was reduced following glutathione administration.
    3 context sentences
    Summary · context
    A total of 16 consecutive patients (15 with ovarian cancer and 1 with unknown adenocarcinoma) were treated with a standard regimen including cisplatin and cyclophosphamide or with the same regimen in combination with reduced glutathione as potential protective agent against cisplatin nephrotoxicity,…
    Summary · context
    Reduced glutathione (1500 mg/m2) was administered prior to each cisplatin administration (90 mg/m2) to seven patients for a maximum of five consecutive courses.
    Summary · context
    A standard hydration protocol without diuretics was used.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients receiving chemotherapy, glutathione pretreatment did not impair therapeutic efficacy compared with the standard regimen without glutathione.

    In plain wordsIn patients receiving chemotherapy, glutathione did not impair treatment effectiveness compared with the standard regimen without glutathione.

    Peptide
    Glutathione
    Outcome
    No significant changeTherapeutic efficacy
    Study

    n = 16

    Comparator
    Standard chemotherapy without glutathione
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1500 mg/m2 · maximum of five consecutive coursesAs given in this study (human).

    Source sentences

    Summary
    Moreover, the therapeutic efficacy was not impaired by glutathione pretreatment.
    3 context sentences
    Summary · context
    A total of 16 consecutive patients (15 with ovarian cancer and 1 with unknown adenocarcinoma) were treated with a standard regimen including cisplatin and cyclophosphamide or with the same regimen in combination with reduced glutathione as potential protective agent against cisplatin nephrotoxicity,…
    Summary · context
    Reduced glutathione (1500 mg/m2) was administered prior to each cisplatin administration (90 mg/m2) to seven patients for a maximum of five consecutive courses.
    Summary · context
    A standard hydration protocol without diuretics was used.
  3. 03HumanNon-randomized trialSafety outcome

    In patients receiving chemotherapy, glutathione produced no appreciable side effects.

    In plain wordsIn patients receiving chemotherapy, glutathione caused no appreciable side effects.

    Peptide
    Glutathione
    Outcome
    No significant changeAppreciable side effects
    Study

    n = 7

    Outcome group
    Adverse events · Whole body
    Studied dose
    1500 mg/m2 · maximum of five consecutive coursesAs given in this study (human).

    Source sentences

    Summary
    Glutathione was well tolerated, since it did not produce appreciable side effects.
    3 context sentences
    Summary · context
    A total of 16 consecutive patients (15 with ovarian cancer and 1 with unknown adenocarcinoma) were treated with a standard regimen including cisplatin and cyclophosphamide or with the same regimen in combination with reduced glutathione as potential protective agent against cisplatin nephrotoxicity,…
    Summary · context
    Reduced glutathione (1500 mg/m2) was administered prior to each cisplatin administration (90 mg/m2) to seven patients for a maximum of five consecutive courses.
    Summary · context
    A standard hydration protocol without diuretics was used.
  4. 04HumanNon-randomized trialSafety outcome

    In patients receiving cisplatin, the cisplatin and glutathione combination produced no unexpected toxicity.

    In plain wordsIn patients receiving cisplatin, the cisplatin and glutathione combination caused no unexpected toxicity.

    Peptide
    Glutathione
    Outcome
    No significant changeUnexpected combination toxicity
    Study

    n = 7

    Outcome group
    Adverse events · Whole body
    Studied dose
    1500 mg/m2 · maximum of five consecutive coursesAs given in this study (human).

    Source sentences

    Summary
    Cisplatin and glutathione combination did not produce unexpected toxicity.
    3 context sentences
    Summary · context
    A total of 16 consecutive patients (15 with ovarian cancer and 1 with unknown adenocarcinoma) were treated with a standard regimen including cisplatin and cyclophosphamide or with the same regimen in combination with reduced glutathione as potential protective agent against cisplatin nephrotoxicity,…
    Summary · context
    Reduced glutathione (1500 mg/m2) was administered prior to each cisplatin administration (90 mg/m2) to seven patients for a maximum of five consecutive courses.
    Summary · context
    A standard hydration protocol without diuretics was used.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.